ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Novartis partners with IFM Due for cGAS/STING inhibitors

by Ryan Cross
September 14, 2019 | APPEARED IN VOLUME 97, ISSUE 36

 

Novartis has formed a partnership with IFM Due, a subsidiary of IFM Therapeutics that is focused on developing inhibitors of the cGAS/stimulator of interferon genes (STING) pathway. Novartis is already developing activators of the STING protein for cancer, and is one of several companies that believes STING inhibitors would make powerful therapies for autoimmune and inflammatory diseases. Novartis will assume all of IFM Due’s R&D costs and may acquire the company for up to $840 million in the future.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment